BOHD, also known as 4-methyl-2,5-dimethoxy-ò-hydroxyphenethylamine or as ò-hydroxy-2C-D, is a drug of the phenethylamine, 2C, and BOx families. It is the ò-hydroxy derivative of 2C-D.
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists BOHD's dose as greater than 50mg orally and its duration as unknown. Its effects have been reported to include a marked drop in blood pressure without any change in heart rate, suggestive of adrenolytic toxicity. Higher doses were not explored and other effects not observed or described.
The chemical synthesis of BOHD has been described.
Analogues of BOHD include BOHB (ò-hydroxy-2C-B), BOD (ò-methoxy-2C-D), and BOB (ò-methoxy-2C-B), among others.
BOHD was first described in the scientific literature by Beng T. Ho and colleagues in 1970. Subsequently it was described in greater detail by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
BOHD is a controlled substance in Canada under phenethylamine blanket-ban language.
This substance is a Class A drug under the UK Misuse of Drugs Act 1971.
In the United States, BOHD is a Schedule I isomer of mescaline.